The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Open-label, multicenter, randomized phase III trial of pemetrexed/carboplatin doublet vs pemetrexed singlet in chemotherapy-naïve elderly patients aged 70 or more with advanced non-squamous non-small cell lung cancer and good performance status.
 
Dae Ho Lee
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Novartis; Pfizer; Samyang
 
Eun Kyung Cho
No Relationships to Disclose
 
Jin Seok Ahn
Honoraria - AstraZeneca; Janssen; Lilly; Menarini; Roche
Consulting or Advisory Role - Boehringer Ingelheim
 
Dong-Wan Kim
No Relationships to Disclose
 
Byoung Chul Cho
Honoraria - AstraZeneca; Boehringer Ingelheim; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Celgene; GlaxoSmithKline; Novartis; Ono Pharmaceutical; Roche
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Novartis
Research Funding - Bayer; Boehringer Ingelheim; Novartis
 
Ki Hyeong Lee
No Relationships to Disclose
 
Sang-We Kim
No Relationships to Disclose